Ratings Warby Parker Inc.

Equities

WRBY

US93403J1060

Market Closed - Nyse Other stock markets 01:30:02 27/04/2024 am IST			5-day change	1st Jan Change
12.92 ^USD	+1.33%		+7.22%	-8.37%

13/03	Warby Parker Insider Sold Shares Worth $290,216, According to a Recent SEC Filing	MT
28/02	Warby Parker Shares Drop After Reporting Q4 Net Loss Narrows, Net Revenue Gains	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
WARBY PARKER INC.	-8.37%	1.54B		C+
ALCON INC.	+9.69%	38.82B		B
THE COOPER COMPANIES, INC.	-6.10%	17.66B		B-
AUTEK CHINA INC.	-20.02%	2.24B		D+
PEGAVISION CORPORATION	+29.63%	1.23B		-
MINGYUE OPTICAL LENS CO.,LTD.	-35.62%	747M		-
MENICON CO., LTD.	-35.36%	735M		B-
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.	-13.36%	623M		-
VIZIONFOCUS INC.	+24.04%	494M	-	-
VISCO VISION INC.	+17.74%	493M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes